Individuals with pancreatic insufficient cystic fibrosis (PI-CF) and glucose intolerance demonstrate impaired incretin and insulin secretion. The goal of this study was to assess β-cell responsiveness to the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) during glucose potentiated arginine (GPA) testing in adults with PI-CF and abnormal glucose tolerance. Participants were randomized to receive either GLP-1 (n=15) or GIP (n=15) and then underwent GPA testing during either incretin or placebo infusion in a randomized, cross-over fashion. OGTT was similar between groups (1hr: 214±8 vs. 208±7 mg/dL; 2hr: 141±18 vs. 150±18 mg/dL). During GPL-1 infusion, fasting glucose was lower after 30 min vs. placebo (p<0.001), and during the 230 mg/dL glucose clamp the glucose infusion rate (GIR) was higher (p<0.001). Second phase insulin levels were substantially increased prior to arginine administration under 230 mg/dL clamp conditions vs. placebo (p<0.001), but no difference in the acute insulin response (AIR) to GPA was present. At 230 mg/dL, proinsulin and C-peptide were increased under GLP-1 vs. placebo (both p<0.001), but the proinsulin secretory ratio (PISR) was unchanged. During GIP infusion, fasting glucose was slightly lower after 30 min vs. placebo (p<0.05), but no difference in the GIR required to achieve 230 mg/dL was found. Second phase insulin levels were not different during the 230 mg/dL glucose clamp. The AIR to GPA was lower during GIP vs. placebo (p<0.01). Second phase proinsulin and C-peptide levels were higher with GIP vs. placebo (both p<0.01) with an increased PISR (p<0.05). These results indicate that GLP-1 augments glucose-dependent insulin secretion while GIP may lead to disproportionate proinsulin secretion in glucose intolerant PI-CF. Further studies should determine whether GLP-1 may provide a therapeutic benefit in this population.


J.N. Eiel: None. S. Nyirjesy: None. A.J. Peleckis: None. D. De Leon: Employee; Spouse/Partner; Merck & Co., Inc.. Research Support; Self; Zealand Pharma A/S. Consultant; Self; XOMA Corporation, ProSciento. Research Support; Self; Biomarin Corporation. D. Hadjiliadis: None. C. Kubrak: None. A. Tami: None. S. Sheikh: None. R.C. Rubenstein: None. A. Kelly: None. M.R. Rickels: Consultant; Self; Hua Medicine, Xeris Pharmaceuticals, Inc..

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at